Cardiol Therapeutics Inc. (CRDL) Stock Price & Analysis
Cardiol Therapeutics Inc. (CRDL) closed at USD 1.15 on Thursday, October 15, 2026, up 0.88% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 1.14; the Oct 15, 2026 session ranged USD 1.13–1.17 on volume of 570,499 shares. Market capitalization is $139.74M, with a 52-week range of USD 0.88–2.34 (NCM). Source: Nexqual, retrieved October 16, 2026 at 05:21 UTC.
Also available as compact Markdown for AI agents: nexqual.com/CRDL.md
Key facts (CRDL)
- Analysts: Buy (mean 1.67 on a 1–5 scale) (6 analysts), mean target USD 8.47 (range 4.99–11.07).
- Total return with dividends: 1Y +10.6% vs S&P 500 +18.1%; 5Y -70.7% vs S&P 500 +85.1%.
- Next earnings: 2026-11-12, EPS estimate USD -0.08, revenue estimate $0K.
Analysts (CRDL)
Consensus Buy (mean 1.67 on a 1–5 scale), 6 analysts; mean target USD 8.47 (low 4.99, high 11.07).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-23 | HC Wainwright & Co. | Reiterated | Buy | $9 |
| 2026-08-17 | Canaccord Genuity | Target raised | Buy | $8 → $10 |
| 2026-07-14 | HC Wainwright & Co. | Reiterated | Buy | $9 |
Total return (dividends reinvested) (CRDL)
| 1Y (from 2025-10-16) | 5Y (from 2021-10-11) | |
|---|---|---|
| Total return | +10.6% | -70.7% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | +10.6% | -21.7% |
| Volatility (annualized) | 62.6% | 79.8% |
| Max drawdown | -50.1% (Sep 2026→Oct 2026) | -89.3% (Oct 2021→Apr 2023) |
Key Statistics (as of October 16, 2026 at 05:21 UTC)
| Price | USD 1.15 |
|---|---|
| Change | ▲ 0.88% (up) |
| Previous Close | USD 1.14 |
| Open | USD 1.16 |
| Day Range | USD 1.13 – 1.17 |
| 52-Week Range | USD 0.88 – 2.34 |
| Volume | 570,499 shares |
| Market Cap | $139.74M |
| Exchange | NCM |
Technical Analysis (CRDL)
Nexqual's technical model rates CRDL "SELL" based on 2 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:21 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 21.39 (oversold) |
| vs SMA50 | Below (USD 1.74) |
| MACD | -0.18 (negative) |
Analyst Ratings (CRDL)
Wall Street analysts rate CRDL "Buy" based on 6 analysts, with a mean price target of USD 8.47 (range USD 4.99–11.07), per Nexqual as of October 16, 2026 at 05:21 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 6 |
| Mean Target | USD 8.47 |
| High Target | USD 11.07 |
| Low Target | USD 4.99 |
| Buy / Hold / Sell | 6 / 0 / 0 |
Earnings (CRDL)
| Next Earnings Date | 2026-11-12 |
|---|---|
| EPS Estimate | USD -0.08 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.05 vs est -0.1 ▲ beat |
| 2026-03-31 | USD -0.1 vs est -0.09 ▼ miss |
| 2025-12-31 | USD -0.07 vs est -0.11 ▲ beat |
| 2025-09-30 | USD -0.12 vs est -0.11 ▼ miss |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Financials & Fundamentals (CRDL)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -190.18% |
| Debt / Equity | 0 |
| Current Ratio | 5.55 |
| Total Cash | $26.08M |
| Total Debt | $106,998 |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Financial Health Score (CRDL)
Nexqual rates Cardiol Therapeutics Inc.'s overall financial health "Mixed" across five dimensions, as of October 16, 2026 at 05:21 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — CAD 26M cash, no debt |
| Cash Flow | Weak — Operating cash flow -CAD 24M (TTM) |
| Efficiency | Critical — ROE -190%, ROA -90.9% |
Ownership (CRDL)
| Insider Ownership | +2.27% |
|---|---|
| Institutional Ownership | +26.38% |
| Shares Outstanding | 121.51M |
| Float | 91.98M |
| Short % of Float | +2.59% |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Leadership (CRDL)
Cardiol Therapeutics Inc. is led by David G. Elsley, President, CEO & Director, per Nexqual as of October 16, 2026 at 05:21 UTC.
| President, CEO & Director | David G. Elsley |
|---|---|
| CFO, Corporate Secretary & Director | Christopher J. Waddick C.A., C.M.A. |
| Chief Operating Officer | Bernard Lim B.Sc. |
| Vice President of Corporate Development | John A. Geddes BSCPT |
Major Backers & Investors (CRDL)
Notable institutional backers of Cardiol Therapeutics Inc. include MMCAP International, Inc. SPC, Tejara Capital Ltd, Ikarian Capital, LLC, according to Nexqual as of October 16, 2026 at 05:21 UTC.
Active Investors
| Investor | Stake |
|---|---|
| MMCAP International, Inc. SPC | 13.12% |
| Tejara Capital Ltd | 4.3% |
| Ikarian Capital, LLC | 2.8% |
| Boothbay Fund Management, LLC | 0.82% |
| Citadel | 0.67% |
| Renaissance Technologies | 0.65% |
| Two Sigma Investments, LP | 0.63% |
| Integrity Alliance, Llc. | 0.33% |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BHC | Bausch Health Companies Inc. | USD 6.31 | ▲ 7.13% |
| HCM | HUTCHMED (China) Limited | USD 13.94 | ▲ 3.26% |
| LQDA | Liquidia Corporation | USD 34.78 | ▲ 29.73% |
| AMLX | Amylyx Pharmaceuticals, Inc. | USD 27.65 | ▲ 2.98% |
| INDV | Indivior Pharmaceuticals, Inc. | USD 33.62 | ▼ 5.08% |
| RGC | Regencell Bioscience Holdings L | USD 9.52 | ▲ 16.24% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:21 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt